Immix Biopharma (IMMX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

IMMX · Stock Price

USD 9.54+7.45 (+356.46%)

Market Cap: $500.2M

Historical price data

Market Cap: $500.2MPipeline: 2 drugsPatents: 5Founded: 2012Employees: 11-50HQ: Los Angeles, United States

Sector Ranking#42 in Cell & Gene Therapy #68 in Oncology (General)

Overview

Immix Biopharma's mission is to harness the immune system through innovative cell therapies to deliver widely accessible cures. The company's core achievement is the development of its N-GENIUS platform, which has produced NXC-201, a CAR-T therapy demonstrating a transformative safety profile with 0% neurotoxicity in AL amyloidosis and high response rates. Its strategy is to overcome the primary barrier to CAR-T adoption—neurotoxicity—to expand into new disease indications and the 95% of U.S. medical centers currently unable to dose existing CAR-T therapies, starting with a planned BLA submission in AL amyloidosis.

OncologyHematology

Technology Platform

N-GENIUS Sterically-Optimized Cell Therapy Platform with EXPAND technology, engineered to dramatically reduce neurotoxicity and cytokine release syndrome while maintaining therapeutic efficacy in CAR-T therapies.

Pipeline

2

2 drugs in pipeline

Drug	Indication	Stage	Watch
Imx-110	Solid Tumor, Adult	Phase 1/2
NXC-201 CAR-T	Light Chain (AL) Amyloidosis	Phase 1/2

Funding History

3

Total raised:$30M

IPO$15MUndisclosedNov 18, 2021

Series A$12MNextech InvestMar 15, 2020

Seed$3MUndisclosedJun 15, 2018

Opportunities

NXC-201 has the potential to be the first approved CAR-T therapy for relapsed/refractory AL amyloidosis, an orphan disease with high unmet need.

Its superior safety profile could enable expansion into the 95% of U.S.

hospitals currently unable to administer CAR-Ts and allow penetration into earlier lines of therapy in larger markets like multiple myeloma.

Risk Factors

Key risks include the failure of the pivotal NEXICART-2 trial to confirm earlier efficacy/safety data, regulatory delays post-BLA submission, challenges in commercializing a first-in-class therapy for a rare disease, and intense competition in the multiple myeloma space from next-generation therapies.

Competitive Landscape

In AL amyloidosis, NXC-201 is a first-mover CAR-T with no direct cell therapy competitors. In multiple myeloma, it faces established, highly efficacious CAR-Ts (Abecma, Carvykti) but differentiates on a potentially best-in-class safety profile, aiming to enable broader, earlier-line use rather than competing on headline efficacy in late-line patients.